Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets

NCT05168683 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperuricemia
Gout

Interventions

DRUG: Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal
DRUG: Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state

Sponsor

Allena Pharmaceuticals

Collaborators

[object Object]